Influence of ethnicity on cyclin-dependent kinase inhibitor efficacy and toxicity: A systematic review and meta-analysis
Background: The combination of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) with endocrine therapy (ET) is the standard of care for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (aBC). While the efficacy and safet...
Saved in:
Main Authors: | Roberto Buonaiuto, Aldo Caltavituro, Margherita Tafuro, Alessandra Longobardi, Giuliana Pavone, Pierluigi De Santis, Roberta Caputo, Carmine De Angelis, Lucia Del Mastro, Fabio Puglisi, Mario Giuliano, Grazia Arpino, Martina Pagliuca, Michelino De Laurentiis |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-02-01
|
Series: | Breast |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0960977624001644 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them
by: L. Foffano, et al.
Published: (2025-02-01) -
Dual Inhibition of CDK4/6 and CDK7 Suppresses Triple‐Negative Breast Cancer Progression via Epigenetic Modulation of SREBP1‐Regulated Cholesterol Metabolism
by: Yilan Yang, et al.
Published: (2025-02-01) -
Induction of cell cycle arrest via the p21, p27–cyclin E,A/Cdk2 pathway in SMMC-7721 hepatoma cells by clioquinol
by: Huang Zhiwei, et al.
Published: (2015-12-01) -
Evaluating the Effectiveness of Cyclin-Dependent Kinase 4/6 Inhibitors in Early- and Very Early-Onset Metastatic Breast Cancer: A Multicenter Study
by: Akif Doğan, et al.
Published: (2025-01-01) -
Validation of a hypomorphic variant in CDK13 as the cause of CHDFIDD with autosomal recessive inheritance through determination of an episignature
by: Jan Fischer, et al.
Published: (2025-01-01)